FindTrial
Sign In

A multicenter clinical retrospective study on the efficacy and safety of Metformin and Empagliflozin Tablets in patients with type 2 diabetes

A multicenter clinical retrospective study on the efficacy and safety of Metformin and Empagliflozin Tablets in patients with type 2 diabetes

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200061489
Enrollment
Unknown
Registered
2022-06-27
Start date
2022-08-01
Completion date
Unknown
Last updated
2023-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes

Interventions

case series:None

Sponsors

The Second Affiliated Hospital of Kunming Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Type 2 diabetes patients (WHO criteria, 1999); 2. Aged >= 18 years.

Exclusion criteria

Exclusion criteria: 1. Moderate to severe renal impairment (eGFR < 45mL/min/1.73m^2), end-stage renal disease or dialysis; 2. Acute or chronic metabolic acidosis, including diabetic ketoacidosis; 3. Have a history of severe allergy to Engliazine, metformin or any excipients of this product.

Design outcomes

Primary

MeasureTime frame
Glycated hemoglobin;Fasting venous glucose;Venous blood glucose 2 hours after meal;—

Secondary

MeasureTime frame
Waist-to-hip ratio;Fasting insulin and C-peptide;Blood pressure;Blood lipids;Blood uric acid;Insulin and C-peptide 2 hours after meal;Weight;Body mass index;—

Countries

China

Contacts

Public ContactKe Tingyu
1574310581@qq.com+86 13808753350

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026